VBWG
Meeting report

OASIS-6 trial

OASIS-6 trial results: The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial




OASIS-6

Download VBWG06-OASIS-6.ppt (14 slides - 1.0MB)

OASIS-6 OASIS-6: Background and hypothesis OASIS-6: Study design OASIS-6: Baseline characteristics OASIS-6: Medical history OASIS-6: Concomitant in-hospital medications following randomization OASIS-6: Treatment effect on primary efficacy outcome at 30 days OASIS-6: Severe bleeding at 30 days OASIS-6: Net clinical benefit OASIS-6: Treatment effect on primary outcome at 30 days–Subgroup analyses OASIS-6: Reduction in death and MI at study end OASIS-6: Conclusion OASIS-6: Summary The OASIS program: Safety and efficacy of fondaparinux in a broad range of patients with ACS



ischemicOASISOrganizationSixthsyndromes

Related at vwbg.org

OASIS-5 trial

OASIS-5 results: The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section IV: Antithrombotic interventions in acute coronary syndromes

The VBWG Core Curriculum 2003 slide lecture compendium Impact of vascular biology in treatment of cardiovascular disease , provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.

Core Curriculum

Impact of vascular biology in treatment of cardiovascular disease Section IV: Antithrombotic interventions in acute coronary syndromes

The VBWG Core Curriculum 2002 slide lecture program, Impact of vascular biology in treatment of cardiovascular disease, covers basic science and clinical advances in vascular biology in a spectrum of disorders.
More related